Market Movers (8-K)
OQB
CTT Pharmaceutical Holdings, Inc. announced the U.S. Patent Office has granted a continuation-in-part patent for its micelle delivery technology, now covering nicotine, vitamins, and caffeine across various oral dosage forms.
Insider Trading (Form 4)
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on August 12, 2026.
OQB
Ctt Pharmaceutical Holdings, Inc. reported changes in beneficial ownership of Ctt Pharmaceutical Holdings, Inc. common stock on August 7, 2026.
New Public Companies (S-1)
OQB
CTT Pharmaceutical Holdings, Inc. has filed an S-1/A amendment to register up to 6,250,000 shares of common stock for resale by RH2 Equity Partners, issued under an Equity Line of Credit.
Capital raise
Delay expected
OQB
CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners, issued under an Equity Line of Credit.
Capital raise
OQB
CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners, issued under a committed equity line of credit.
Capital raise
OQB
CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement detailing the potential resale of up to 6,250,000 shares of common stock by RH2 Equity Partners.
Capital raise
OQB
CTT Pharmaceutical Holdings, Inc. filed an amended S-1 registration statement to facilitate a $10 million equity line of credit with RH2 Equity Partners.
Capital raise